Cummings Keith's most recent trade in Pliant Therapeutics Inc was a trade of 400,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 22, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2026 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.28 per share. | 20 Jan 2026 | 24,002 | 297,214 | - | 1.3 | 30,723 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 113,300 | 113,300 | - | - | Stock Option (Right to Buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 56,650 | 319,258 | - | 0 | Common Stock | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.20 per share. | 17 Jan 2025 | 20,148 | 262,608 | - | 11.2 | 225,680 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.56 per share. | 10 Jul 2024 | 10,911 | 282,115 | - | 11.6 | 126,131 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2024 | 21,313 | 293,026 | - | 0 | Common Stock | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2024 | 21,000 | 76,047 | - | - | Stock Option (Right to Buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 02 May 2024 | 21,000 | 271,713 | - | 2.1 | 43,680 | Common Stock |
| Pliant Therapeutics Inc | Cummings Keith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 110,500 | 110,500 | - | - | Stock Option (Right to Buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 55,250 | 249,855 | - | 0 | Common Stock | |
| Pliant Therapeutics Inc | Cummings Keith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.23 per share. | 17 Jan 2024 | 9,781 | 194,605 | - | 17.2 | 168,527 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 17 Jul 2023 | 19,771 | 203,999 | - | 18.0 | 356,058 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 38,750 | 223,770 | - | 0 | Common Stock | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 09 Jun 2023 | 5,800 | 154,270 | - | 2.1 | 12,064 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2023 | 5,800 | 127,797 | - | - | Stock Option (Right to Buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.52 per share. | 30 Mar 2023 | 9,960 | 148,470 | - | 26.5 | 264,148 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 19,375 | 158,430 | - | 0 | Common Stock | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 76,200 | 76,200 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 54,000 | 138,424 | - | 0 | Common Stock | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 23 Jan 2023 | 30,000 | 84,424 | - | 35 | 1,050,000 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 17,500 | 18,198 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.22 per share. | 23 Jan 2023 | 17,500 | 114,424 | - | 6.2 | 108,850 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 23 Jan 2023 | 12,500 | 96,924 | - | 2.1 | 26,000 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 12,500 | 133,597 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 22 Dec 2022 | 4,000 | 84,424 | - | 2.1 | 8,320 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2022 | 4,000 | 146,097 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 19,375 | 90,067 | - | 0 | Common Stock | |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.10 per share. | 19 Dec 2022 | 9,643 | 80,424 | - | 19.1 | 184,204 | Common Stock |
| Pliant Therapeutics Inc | Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 124,000 | 124,000 | - | - | Stock Option (right to buy) |